On Oct. 5, 2020, Corvus Pharmaceuticals announced that it has initiated a Phase 1 study to investigate a novel immunotherapy approach for patients with COVID-19. The first cohort of five patients enrolled in the study was treated at Temple University Hospital in Philadelphia, PA.

The study was expected to enroll up to 30 patients at several sites in the U.S. This followed the FDA’s review and acceptance of the Company’s investigational new drug (IND) application for the COVID-19 study.